Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

Documenti analoghi

• Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
  di: Satoshi Kawano, et al.
  Pubblicazione: (2016-01-01)
• Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
  di: Sarah K Knutson, et al.
  Pubblicazione: (2014-01-01)
• EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma
  di: Muhammad Mushtaq, et al.
  Pubblicazione: (2024-11-01)
• Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
  di: Changchien Yi-Che, et al.
  Pubblicazione: (2012-10-01)
• Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
  di: Haruka Shinohara, et al.
  Pubblicazione: (2022-12-01)